## Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

## **Listing of Claims:**

1. (previously presented) A compound of the general formula (I):

wherein R' represents an anti-epileptic drug, anticonvulsive drug, neuroprotective drug, neurotransmitter or nootrope moiety;

R is selected from the group consisting of - $CH_2OH$ , -CHO and - $CH_2NH_2$ ; and pharmaceutically acceptable salts thereof.

- 2. (original) The compound according to claim 1, wherein R' is an anti-epileptic drug moiety.
- 3. (previously presented) The compound according to claim 2, wherein said anti-epileptic drug is selected from the group consisting of phenytoin and other hydantoins; phenobarbital and other barbiturates, primidone, carbamazepine and oxacarbamazepine, valproic acid or its derivatives; oxazolidines; benzo-diazepines; felbamate, gabapentin, lamotrigine, vigabatrin and adrenocorticotropic hormone (ACTH).
- 4. (original) The compound according to claim 1, wherein R' represents a moiety of y-aminobutyric acid and/or kynurenic acid.
- 5. (canceled)
- 6. (original) The composition according to claim 5, wherein component (b) is an

anti-epileptic drug.

## 7. (canceled)

8. (previously presented) A pharmaceutical composition comprising a therapeutically effective amount of the compound of the general formula (I)

and a pharmaceutically acceptable carrier or excipient, wherein R' represents an anti-epileptic drug, anticonvulsive drug, neuroprotective drug, neurotransmitter or nootrope moiety; and

R is selected from the group consisting of -CH<sub>2</sub>OH, -CHO and -CH<sub>2</sub>NH<sub>2</sub>; and pharmaceutically acceptable salts thereof.

- 9. (previously presented) The pharmaceutical composition according to claim 8, wherein the compound of the general formula (I) having R' in an amount which is no greater than the maximal safe amount for a single administration of the attached anti-epileptic drug, anticonvulsive drug, neuroprotective drug, neurotransmitter or nootrope component.
- 10. (original) A pharmaceutical composition comprising therapeutically effective amounts of components (a) and (b) as defined above in claim 5, and at least one pharmaceutically acceptable carrier, diluent, or excipient.
- 11. (original) The pharmaceutical composition according to claim 10, wherein components (a) and (b) are present in dosages no greater than their respective maximal safe dosages for a single administration.
- 12. (withdrawn) A method of treatment of a neurological disease or disorder comprising

administering to an individual in need thereof a therapeutically effective amount of a compound of the general formula (I):

wherein R' represents an anti-epileptic drug, anticonvulsive drug, neuroprotective drug, neurotransmitter or nootrope moiety; and

R is selected from the group consisting of -CH<sub>2</sub>OH, -CHO and -CH<sub>2</sub>NH<sub>2</sub>; and pharmaceutically acceptable salts thereof.

13 to 14. (canceled)

15. (withdrawn) The method of claim 12, wherein said neurological disease or disorder is epilepsy.

16. (withdrawn) A method for preventing epileptic episodes, alleviating epileptic episodes and/or reducing side effects of anti-epileptic drugs comprising the step of administering to a subject a therapeutically effective amount of a compound of the general formula (I):

wherein R' represents an anti-epileptic drug, anticonvulsive drug, neuroprotective drug, neurotransmitter or nootrope moiety; and

R is selected from the group consisting of -CH<sub>2</sub>OH, -CHO and -CH<sub>2</sub>NH<sub>2</sub>; and pharmaceutically acceptable salts thereof.

## 17. (canceled)

18. (withdrawn) The method according to claim 12, wherein said compound is orally administered.

19 to 24 (canceled).